Latest HVIVO Press Release: 06.08.19 hVIVO Successfully Completes RSV Challenge Study in Older Adults
Industry leading provider of viral challenge studies
hVIVO’s shares are listed on the AIM market of
the London Stock Exchange under the HVO ticker.
This area is dedicated to keeping shareholders and potential investors informed.
A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.
Our Mission is to build a profitable clinical development services business supporting product development for our clients through human challenge studies to establish early proof of concept.
FluCamp is hVIVO’s clinical trial volunteer recruitment brand. Find out more at www.flucamp.com.